Effective April 10, 2023, masking is optional in all NYOH sites for patients and employees.
Make First Appointment Refer a Patient

Clinical Trials & Research

Home / Clinical Trials & Research / View Open Trials

View Open Trials

Breast
Cholangiocarcinoma
Colon
Colorectal
Gall Bladder
Lung (Non Small Cell)
Lymphomas
Other
Prostate
Renal
Solid Tumors

Breast

  • 22101 - Ph3 Imlun vs Endo ER+ HER2- BC

    EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • 22159 - Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

    A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

  • 20396 - Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

    A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

  • 20210 - Registry study with Breast Cancer Index

    Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

  • 17079 - FLEX Registry: Evaluate New Gene Express

    MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Cholangiocarcinoma

  • 22147 - Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

    A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Colon

  • 21386 - Ph2 RO7198457 CRC ctDNA+ Post Resection

    A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01

  • 21385 - Ph2 Epidemi Colon Cancer

    Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Colorectal

  • 21386 - Ph2 RO7198457 CRC ctDNA+ Post Resection

    A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01

Gall Bladder

  • 22147 - Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

    A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Lung (Non Small Cell)

  • 22107 - PH2 MORab-202 NSCLC

    A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • 22285 - MYLUNG Consortium Part 3: Observational Study

    Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

  • 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

    A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

  • 20412 - Ph3 Adj Selp St1B/3 RET+ NSCLC

    A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

  • BIODESIX

    Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

Lymphomas

  • 21356 - Ph2 Sub Mosunetuzumab B-cell malig

    AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Other

  • 22147 - Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

    A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Prostate

  • 21493 - PH3 Place Capi+ Doce Place+ Doce mCRPC

    A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

  • 20248 - PH3 Nirap Abira HRR mCSPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Renal

Solid Tumors